ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 19

Citrulline-Multispecific B Cell Receptor Clades in Rheumatoid Arthritis

Philip J. Titcombe1,2, Natalie Sippl3, Monika Hansson4, Lena Israelsson3, Khaled Amara3, Timothy B. Niewold5, Lars Klareskog2, Vivianne Malmström2 and Daniel L. Mueller6, 1The Center for Immunology, Dept. of Medicine, University of Minnesota Medical School, Minneapolis, MN, 2Rheumatology Unit, Dept. of Medicine, Karolinska Institutet, Stockholm, Sweden, 3Rheumatology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, 4Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 5Colton Center for Autoimmunity, New York University, New York, NY, 6Medicine/Rheumatic and Autoimmune Diseases, University of Minnesota Medical School, Minneapolis, MN

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: anti-citrullinated protein/peptide antibodies (ACPA), B cells, immunoglobulin (IG) and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, October 21, 2018

Title: B Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Anti-citrullinated protein antibodies (ACPA) have proven highly useful as biomarkers in rheumatoid arthritis (RA) and appear to be important to disease pathogenesis. Nevertheless, the relationship between progressive B cell receptor (IGH, IGK, and IGL) gene somatic hypermutation (SHM) and citrullinated protein antigen specificity in RA B cells remains only poorly understood. In this investigation, we aimed to characterize citrullinated peptide reactivity as a function of heavy and light chain SHM events using a panel of citrullinated autoantigen–specific RA B cells.

Methods: Three subjects from the University of Minnesota ACPA+ RA cohort gave consent for the study of peripheral blood B cell receptor antigen specificity. Citrullinated filaggrin peptide (CFC1) and citrullinated a-enolase peptide (CEP-1) tetramer–bound B cells were subjected to flow cytometric cell sorting and single-cell IGH, IGK, and IGL gene sequencing. BCR genes demonstrating related V-(D)-J region gene usage and conserved junction structures were compared using the PHYLIP/DNApars algorithm and B cell lineage relationships (clades) were characterized. BCR gene sequences were also expressed as recombinant monoclonal antibodies (mAbs) for direct evaluation of citrullinated antigen binding by ELISA.

Results: Paired heavy and light chain Ig gene sequences were obtained at a single time point from subjects RA14 (n = 9) and RA62 (n = 10). Additionally, 86 paired nucleotide sequences were obtained from subject RA37 at three separate time points. Parsimonious clustering of related immunoglobulin gene nucleotide sequences revealed that 52 of these 105 B cells (50%) arose within 9 unique clades as a consequence of clonal expansion and progressive SHM. The frequency of clade membership by citrullinated peptide tetramer-bound B cells in each subject varied from 44% to 89% (χ2 = 7.0, P-value = 0.030). The distribution of clade membership by CEP-1 tetramer-bound B cells in subject RA37 also varied significantly across time (χ2 = 25.9, P-value = 0.011). In ELISA, 9 of 20 recombinant human mAbs (45%) generated from a sample of these BCR sequences proved capable of binding to at least one citrullinated antigen, and all 9 of these citrullinated peptide-binding mAbs derived from a highly mutated clade-associated B cell. Citrulline–dependent cross-reactivity (citrulline multispecificity) extending beyond the citrullinated peptides used for B cell capture was observed in all clade-derived mAbs tested.

Conclusion: Our findings suggest that the acquisition of broad ACPA specificity in RA arises from a restricted repertoire of continuously evolving citrulline–multispecific B cell clades.


Disclosure: P. J. Titcombe, None; N. Sippl, None; M. Hansson, None; L. Israelsson, None; K. Amara, None; T. B. Niewold, EMD Serono, 2; L. Klareskog, None; V. Malmström, None; D. L. Mueller, None.

To cite this abstract in AMA style:

Titcombe PJ, Sippl N, Hansson M, Israelsson L, Amara K, Niewold TB, Klareskog L, Malmström V, Mueller DL. Citrulline-Multispecific B Cell Receptor Clades in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/citrulline-multispecific-b-cell-receptor-clades-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/citrulline-multispecific-b-cell-receptor-clades-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology